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Themechanistic basis for the progressive accumula-
tion of Y135F Nef mutant viruses in the HIV-1-infected
population remains poorly understood. Y135F viruses
carry the 2F mutation within RW8 and RF10, which
are two HLA-A*24:02-restricted superimposed Nef
epitopes recognized by distinct and adaptable
CD8+ T cell responses. We combined comprehen-
sive analysis of the T cell receptor repertoire and
cross-reactive potential of wild-type or 2F RW8-
and RF10-specific CD8+ T cells with peptide-MHC
complex stability and crystal structure studies. We
find that, by affecting direct and water-mediated
hydrogen bond networks within the peptide-MHC
complex, the 2F mutation reduces both TCR and
HLA binding. This suggests an advantage underlying
the evolution of the 2F variant with decreased CD8+
T cell efficacy. Our study provides a refined under-
standing of HIV-1 and CD8+ T cell co-adaptation at
the population level.INTRODUCTION
CD8+ cytotoxic T lymphocytes (CTLs) play a critical role in the
control of HIV-1 replication during acute and chronic phases of
infection (Appay et al., 2008; Borrow et al., 1997; Deng et al.,
2015; Koup et al., 1994; Schmitz et al., 1999). However, HIV-1
can escape from the host immune system through Nef-mediated
downregulation of cell-surface human leukocyte antigen (HLA)
class I molecules (Collins et al., 1998; Tomiyama et al., 2002,
2005), as well as by the selection of escape mutations in various
HIV-1 proteins (Goulder and Watkins, 2004; Kawashima et al.,
2009; Kuse et al., 2014). Amino acid substitutions, indeed, occur
at critical sites within HIV-1 CTL epitopes, and their flanking re-Ce
This is an open access article under the CC BY-Ngions and can affect antigen presentation as well as reduce
epitope-HLA binding and weaken T cell receptor (TCR) recogni-
tion (Altman and Feinberg, 2004; Bailey et al., 2004; Goulder and
Watkins, 2004). Earlier studies at the population level revealed
that some of these amino substitutions are HLA-adapted muta-
tions, highlighting the fundamental role of HLA-restricted im-
mune responses in driving and shaping HIV-1 evolution in vivo
(Carlson et al., 2015; Chikata et al., 2014; Kawashima et al.,
2009; Moore et al., 2002). Although CTLs specific for these
escape mutations are not evoked in most cases, the emergence
of some HIV-1 mutants has been associated with the rise of new
T cell repertoires (Akahoshi et al., 2012; Allen et al., 2005; Feeney
et al., 2005; Melhem et al., 2014; Ueno et al., 2007).
The dynamic interaction between CTL response and HIV-1
evolution has been investigated in B27-restricted, HIV-1 Gag-
derived KK10-specific CTLs. Highly effective wild-type (WT)-
specific CTLs carrying the public TCR clonotype TRBV4-3/
TRBJ1-3 can control HIV-1 replication at a relatively early phase
of the infection (Almeida et al., 2007), whereas an escape muta-
tion at position 6 (L286M) in KK10 can evade this CTL recognition
(Iglesias et al., 2011). An emerging T cell repertoire, in particular,
one carrying TRBV6-5/TRBJ1-1, which recognizes both WT and
the L268M mutant—can be recruited and control the L286M
mutant virus (Ladell et al., 2013; Lichterfeld et al., 2007). How-
ever, in some individuals, this cross-reactive CTL can drive a
second mutation at position 2 (R264K) in KK10, resulting in total
abrogation of the binding of the KK10 epitope to the HLA-B27
molecule, loss of control of the R264K mutant virus, and TCR
clonal extinction. Although these studies exemplify the co-adap-
tation between HIV-1 and the T cell response, little is known
about the adaptation of the CD8+ T cell repertoire to escape
mutation epitopes that can still be processed and presented to
T cells.
A Y-to-F substitution at the second position (2F) of RW8
(RYPLTFGW) and RF10 (RYPLTFGWCF) superimposed with
epitopes derived from HIV-1 Nef protein from Japanese HIV-1-
infected individuals and in Caucasians. This substitution isll Reports 15, 2279–2291, June 7, 2016 ª 2016 The Authors. 2279
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. In Vitro Selection of 2F Mutant Virus by RW8- and RF10-Specific CTLs
(A) The ability of clone CTL-52 to suppress WT (open circle) and mutant (close circle) virus replication was determined by performing a viral suppression assay.
Cultured CD4+ T cells derived from a HLA-A*24:02+ healthy donor were infected withWT or 2F virus and then co-cultured with the CTL clone at various E:T ratios.
(B andC) In vitro selection of viral mutant by RW8- and RF10-specific CD8+ CTL clones.Mixtures of paired virus (WT and the 2F virus at a ratio of 9:1) were used to
infect cultured primary CD4 T cells. The infected cells were then co-cultured with an RW8-specific CTL clone (CTL 52) or an RF10-specific one (CTL 170) at an E:T
ratio of 1:1. The production of p24 in the culture supernatant was measured by performing p24 ELISA at day 7 post-infection (B). Results are presented as the
mean ± SD of data from triplicate assays (*p < 0.05; **p < 0.01). The population change in the viral mixture was determined by the relative peak height on the
sequencing electrogram (C).
(D) Replication kinetics of theWT and 2Fmutant virus in primary CD4 T cells. Profiles of replication kinetics of WT (open circles) and 2F (closed circles) are shown.
(E) The cytolytic activities of a representative HLA-A*24:02-restricted RW8-specific CTL clone (CTL-52) toward C1R-A2402 cells pulsed with the indicated
peptide at various concentrations were measured. They were tested at an E:T ratio of 2:1.
(legend continued on next page)
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associated with the presence of HLA-A*24:02 (Carlson et al.,
2012; Chikata et al., 2014). HLA-A*24:02 is the most frequent
HLA class I allele in Japan, being found in approximately 70%
of Japanese individuals (Saito et al., 2000). Interestingly, RW8
and RF10 immunodominant CTL epitopes elicit entirely distinct
CTL responses (Sun et al., 2014). RF10-specific CTLs display
higher TCR diversity and functional avidity than RW8-specific
CTLs, making them the main driver for the selection of the 2F
mutant in vivo. However, RF10-2F mutant-specific CTLs can
be elicited after the emergence of the 2F mutant HIV-1 in HIV-
1-infected HLA-A*24:02+ individuals (Fujiwara et al., 2008). The
exact process leading to the accumulation of the 2F mutant in
HIV-1-infected Japanese individuals remains unclear. Several
questions pertaining to this complex interaction between the vi-
rus and the CTL responses need to be addressed. For example,
do CTLs specific for these two epitopes select the same escape
mutation through different mechanism? What is the effect of this
mutation on the induction of 2F-specific CTLs de novo and on
the recruitment of new clonotypes? It remains unclear why the
2F mutant accumulates in Japanese HIV-1-infected individuals
rather than reverting to theWT in the presence ofmutant-specific
CTLs.
To address these questions, we compared the pressure
exerted by RW8- or RF10-specific CTLs on the selection of the
2F mutant, investigated the effects of this mutation on the elici-
tation of new CTL repertoires by using TCR analysis at a
single-cell level, and analyzed peptide-HLA-A*24:02 crystal
structures and the stability of peptide binding. Our combined
data provide refined mechanistic insight into the co-adaptation
of HIV-1 and the CD8+ T cell response at the TCR-peptide bind-
ing HLA (p-HLA) level.
RESULTS
In Vitro Selection of 2F Mutant by RW8- or RF10-
Specific CTLs
To study the ability of RW8- or RF10-specific CTLs to select the
2F mutant, we performed a competitive replication suppression
assay using WT and 2F mutant viruses. First, we assessed the
ability of RW8- or RF10-specific CTL clone established from pa-
tient KI-158 to suppress WT and 2F mutant viruses. In line with
the higher functional avidity of RF10-specific CTLs (Fujiwara
et al., 2008; Sun et al., 2014), the ability of a representative domi-
nant RF10-specific CTL clone CTL170 to suppress HIV-1 was
stronger than that of a representative dominant RW8-specific
CTL clone CTL52 (Figure 1A), suggesting that RF10-specific
CTLs may have effectively selected the 2F virus. Nonetheless,
in a competitive HIV-1 suppression assay with target cells in-
fected with a mixture of WT and mutant virus at a ratio of 9:1,
respectively (Figure 1B), we did not observe any significant
difference in the selection of the 2F mutant between RW8-
and RF10-specific CTL clones (Figure 1C), indicating that both
CTLs could effectively select 2F viruses. Also, the kinetics of(F) HLA-A*24:02-restricted clones CTL 52 and CTL 170 were stained with RW8 o
(mean fluorescence intensity) of the CTL clones is presented.
(G) HLA-A*24:02-restricted CTL 52 clone and PBMCs from individual KI-158 we
centration of each tetramer. The percentage of tetramer-positive cells among CDvirus replication was not different between WT and 2F viruses
(Figure 1D). These results support the idea that, like RF10-spe-
cific CTLs, RW8-specific CTLs also could contribute to the
selection of the 2F mutant in vivo.
Cross-Recognition of WT and 2F Mutant Epitopes by
RW8-Specific CTLs
Although the RF10-specific CTL clone CTL170 shows a stronger
specificity for the WT epitope than for the 2F mutant (Fujiwara
et al., 2008), the specificity of RW8-specific CTLs for WT and
the 2F mutant remains unknown. To address this point, we
tested RW8-specific CTL clone CTL52 reactivity toward the
RW8-WT and RW8-2F peptides. This clone killed both RW8-
WT and RW8-2F peptide loaded-HLA-A*24:02+ C1R cells with
similar efficacy (Figure 1E). The same result was found for
another RW8-specfic CTL clone established from KI-158 (Fig-
ures S1A–S1C). In addition, we performed direct assessment
of TCR binding avidity for HLA-A*24:02-WT or -2F peptide com-
plexes by using tetramer binding assay on clones CTL52 and
CTL170. The RW8 cross-reactive T cell clone (CTL52) TCR had
the same avidity for both HLA-A*24:02-WT and HLA-A*24:
02-2F peptide complexes (Figure 1F). In contrast, the TCR of
an RF10-specific T cell clone had a stronger avidity for the
HLA-A*24:02-WT peptide complex than for the HLA-A*24:02-
2F peptide complex (Figure 1F). The cross-reactivity of RW8-
specfic CTLs was validated by staining ex vivo peripheral blood
mononuclear cells (PBMCs) from the same individual (KI-158) by
using the same tetramers (Figure 1G). Taken together, these re-
sults indicated that RW8-specific CTLs could cross-recognize
both RW8-WT and RW8-2F epitopes and that the selection of
the 2F mutant by RW8-specific CTLs may have resulted from
another mechanism, such as reduced antigen presentation of
the 2F mutant in 2F virus-infected cells.
Induction of RW8/RF10 2F-Specific CTLs in HLA-
A*24:02+ HIV-1-Infected Individuals
To address the impact of the 2F mutant on RW8/RF10-specific
CTLs, we performed longitudinal analysis of four HLA-A*24:02-
positive individuals (KI-092, KI-102, KI-158, and KI-161) who
were initially infected with the WT virus and later selected the
2F variant virus. We analyzed PBMCs at early (WT) and chronic
(2F) phases of their HIV-1 infection by using four tetramers
(RW8-, RW8-2F-, RF10-, and RF10-2F tetramers). All four indi-
viduals displayed RF10-specific CTLs at the early (WT) phase
and RF10-2F-specific CTLs after the emergence of the 2F virus
(Figure 2), in line with our previous observations (Fujiwara
et al., 2008). Notably, RW8 cross-reactive CTLs were detected
in KI-102 and KI-158 before and after the emergence of the
mutant virus, although the frequency of the CTLs went from
1.6p% to 0.04% in KI-102 after 2.5 years (Figure 2). KI-161
had a high frequency (2.94%) of RW8-specific CTLs at the
WT phase but did not have RW8 cross-reactive CTLs at both
WT and 2F phases. Taken together, these results indicate thatr RW8-2F tetramers at 0.1 nM to 300 nM concentrations of each tetramer. MFI
re competitively stained with RW8 and RW8-2F tetramers at a 300 nM con-
8+ cells was measured.
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Figure 2. Longitudinal Analysis of RW8- and RF10-Specific CTLs before and after Emergence of Mutant Viruses
PBMCs were collected at two different time points (before and after emergence of the mutant virus) from four HIV-1-infected individuals (KI-092, KI-102, KI-158,
and KI-161) and competitively stained with the combination of RW8 and RW8-2F tetramers or RF10 and RF10-2F ones at a 300 nM concentration of each
tetramer. The percentage of tetramer-positive cells amongCD3+CD8+ 7-AAD T cells wasmeasured. Background levels of the tetramer-positive CD3+CD8+ cells
were calculated from the frequencies (mean + 2 SD) of tetramer-positive CD3+CD8+ cells among PBMCs from five HIV-1-naive individuals. See also Figure S1F.the emergence of the 2F virus was associated with the differen-
tial induction of 2F-specific T cells between RW8 and RF10.
Distinct Clonotypic Patterns between RF10 and
RF10-2F-Specific T Cells
Previous studies showed that RF10-2Fmutant-specific CTLs are
elicited in HLA-A*24:02+ individuals who were primarily infected
with the 2F virus or after emergence of this virus in those primarily
infectedwith theWT virus, suggesting that themutant epitope vi-
rus induced new T cell repertoires (Fujiwara et al., 2008; Tanuma
et al., 2008). To clarify the change in T cell repertoires pre-versus
post-emergence of the 2F virus, we performed clonotypic anal-
ysis of RF10- and RF10-2F-specific CTLs to compare the TCR2282 Cell Reports 15, 2279–2291, June 7, 2016clonotype between the two CTLs. We stained PBMCs from indi-
viduals having the 2F mutant virus with both WT and 2F tetra-
mers and sorted tetramer-positive cells at the single-cell level
for TCR analysis. When we sequenced the TCRs of RF10-WT-
or RF10-2F-specific CTLs from seven individuals (Figure S1E;
Table S1), we found that the clonotype of RF10-2F-specific
CTLs was completely different from that of RF10-specific CTLs
(Figures 3A and S2). In addition, we performed a longitudinal
analysis on three additional individuals (KI-092, KI-158, and
KI-161) who had RF10-WT-specific CTLs at an earlier phase of
their infection and then shifted toward a RF10-2F-specific CTL
response after the emergence of the 2F virus (Figure 2). RF10
WT-specific and 2F-specific CTLs showed no overlapping
clonotypes in these individuals (Figures 3D and S4). This finding
indicated that the 2F was a mutant epitope escaped from TCR
recognition and that its emergence resulted in the induction of
a new RF10-2F-specific T cell repertoire in HLA-A*24:02+ indi-
viduals primarily infected with theWT virus. There were no differ-
ences betweenRF10-WT-specific andRF10-2F-specific CTLs in
terms of a (Figure 3B) and b TCRdiversity (Figure 3C). Altogether,
these results support the notion that the induction of T cells with
high TCR diversity can be driven by a featured epitope in the
case of RF10-WT/RF10-2F-specific CTLs (Sun et al., 2014).
Minimal Impact of 2F Virus Emergence on RW8-Specific
T Cell Repertoire
Next, we analyzed the clonotypic composition of RW8-specific
T cells from five individuals with the 2F virus and compared
them with those from the four previously analyzed individuals
having the WT virus (Sun et al., 2014). Flow cytometry analysis
of PBMCs stained with RW8 and RW8-2F tetramers together
showed that RW8-specific CTLs were stained with both tetra-
mers, suggesting that these cells were cross-reactive for RW8-
WT and RW8-2F epitopes (Figures 4 and S1D). Therefore, we
sorted these RW8 cross-reactive T cells to analyze their TCR
at the single-cell level and compared them with the cross-reac-
tive T cells at the early (WT) phase (Figure 4A). In line with RW8
cross-reactive T cells at this phase, the cross-sectional analysis
demonstrated a few clonotypes with a dominant one among
each individual in RW8 cross-reactive T cells at the 2F phase
(Figure 4A). Although the individuals used different a chains, a
high prevalence of public TRBV7-9 gene usage with similar
CDR3 regions (V7-9*01/03-D1*01-J1/J2-5*01) in individuals in-
fected with WT or 2F viruses was found (Figure S3). This finding
implies two possibilities that new cross-reactive CTLs were
induced by the RW8-2F variant and that cross-reactive memory
CTLs from theWT phase remained after the emergence of the 2F
virus. To clarify these possibilities, we performed a longitudinal
analysis of the KI-158 individual at both the WT and 2F phases.
We observed the same dominant clonotype in RW8-specific
CTLs at both phases, indicating that cross-reactive memory
T cells had been primed at the WT phase rather than that the
recruitment of new T cells by the emergence of the 2F mutant
had occurred (Figure 4B and S4). To further clarify the ability of
RW8-2F to recruit new CTLs, we analyzed three individuals
who had first been infected with a 2F virus. RF10-2F-specific
CTLs were detected in all three individuals, whereas RW8-WT/
RW8-2F cross-reactive T cells were not (Figure 4C), suggesting
that the RW8-2F epitope seemingly had no ability to elicit new
CTL repertoires.
Conformational Differences among Peptide-HLA-
A*24:02 Structures
To obtain molecular insights into the impact of the 2F mutation,
we determined the crystal structures of HLA-A*24:02-RF10-2F
and HLA-A*24:02-RW8-2F (Table S2) and compared them with
previously published HLA-A*24:02-RF10 and HLA-A*24:02-
RW8 structures (Sun et al., 2014). Overall, WT and 2F mutant
peptides/HLA-A*24:02 structures shared similar conformations
(Figure 5A), except for minor differences at the position 1 of
RF10 and RF10-2F (Figure S5A). However, major differences be-tween HLA-A*24:02 WT and 2F peptide structures were
observed in terms of hydrogen bond and water molecule levels.
The 8-mer and 10-mer 2F mutant peptides had lost one critical
hydrogen bond contact between the P2 residue and the HLA-
A*24:02 H70 residue (Figures 5B and 5C) that was present in
the 8-mer and 10-mer WT peptides bound to HLA-A*24:02. The
sum of the observed differences may account for a decreased
affinity of HLA-A*24:02 for mutant 2F peptides. Another inter-
esting result of the analysis concerned the distribution of water
molecules in the peptide-binding grooves of different HLA-
A*24:02-peptide complexes. The unambiguous electron density
of water molecules clearly showed their distinct distribution
among fourpeptide/MHCs (major histocompatibility complexes),
whichmight havecontributed tochanges in TCR recognition (Fig-
ures S5B and S5C). The number of water molecules in the vicinity
of HLA-A*24:02-bound 8-merWT and 2F peptides was identical,
but the molecules differed in their positions (Figures 6A and 6B).
In contrast, HLA-A*24:02-RF10-WT showed six water-molecule-
mediated hydrogen bonds; whereas HLA-A*24:02-RF10-2F
harbored eight of them. The position of the water molecules
differed particularly around peptide residue P5 (Figures 6C and
6D). As the 10-mer peptide displayed a conformation with an
exposed central region (P5–P7), this differential distribution of
water molecules around peptide residue P5 might have affected
the TCR recognition.
Effect of the 2F Mutation on Peptide-HLA Binding
Stabilization and T Cell Recognition
The structural analysis suggested that the 2F mutation affected
the stability of the peptide-HLA-A*24:02 complex. To address
this point, we performed a peptide-MHC dissociation assay us-
ing RMA-S-HLA-A*24:02 cells (Figure 7A). The stability of pep-
tide binding was presented as the time required for 50% decay
of the HLAmolecules (DT50). The results indicated that the stabil-
ity of the RF10-WT peptide-HLA-A*24:02 complex was higher
than that of the RF10-2F one (DT50: 6.22 ± 0.09 hr versus
3.35 ± 0.70 hr), indicating that the 2F mutation indeed affected
the stability of peptide-HLA binding. Similarly, the stability of
RW8 peptide binding to HLA-A*24:02 was higher than that of
the RW8-2F one (DT50: 4.37 ± 0.75 hr versus 0.85 ± 0.31 hr).
Next, we investigated the effect of the reduced peptide stability
on the recognition of RW8-specific or RF10-specific CTL clones.
The RW8-specific CTL clone CTL 52, which showed a similar
specific lysis activity toward target cells prepulsed with RW8-
WT or RW8-2F peptides (Figure 1E), recognized the RW8-WT
peptide better than the RW8-2F one during 1–6 hr of incubation
(Figure 7B, left). Similarly, RF10-specific clone CTL189, which
cross-recognizes RF10-WT andRF10-2F at a high concentration
of exogenous peptides (Fujiwara et al., 2008), showed reduced
ability to recognize the RF10-2F peptide as compared with the
ability to recognize the RF10-WT one (Figure 7B, right). Taken
together, these results indicate that the 2F mutation affected
specific CTL recognition since it reduced the stability of pep-
tide-HLA binding. In addition to being a TCR-binding escape
mutant (in the case of RF10, but not RW8), the 2F variant was
also anHLA-binding escapemutant, thus explaining the irrevers-
ible nature of this mutant and accumulation in a population
comprising HLA-A*24:02 individuals.Cell Reports 15, 2279–2291, June 7, 2016 2283
Figure 3. Different Patterns of TCR Clonotypes between RF10-WT- and RF10-2F-Specific T Cells
(A) RF10-2F tetramer-positive CTLs were sorted from patients who carried RF10-2F-specific CTLs (n = 7), and the TCRswere analyzed at the single-cell level. The
usage of the TRAV gene (left) and TRBV gene (right) was compared for the patients (n = 4) carrying RF10-WT-specific CTLs. TCRs were analyzed by use of the
IMGT tool, and the designation of each gene followed IMGT TCR gene nomenclature.
(legend continued on next page)
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Figure 4. Effect of the Emergence of the 2F Virus on Induction of RW8-Specific T Cell Repertoire
(A) RW8/RW8-2F tetramer dual-positive CD8+ T cells were sorted from individuals (n = 5) who carried RW8 CTLs, and then the TCRs were analyzed at the single-
cell level. The usage of the TRAV gene (left) and TRBV gene (right) was compared for the patients (n = 4) carrying cross-reactive RW8 CTLs.
(B) Each tetramer-positive CTL was sorted from longitudinal PBMC samples from individual KI-158 for TCR repertoire analysis at the single-cell level. Paired
TCR a- and b-chain usages are shown.
(C) Staining of PBMCs from three patients and one healthy donor with the combination of RW8 and RW8-2F tetramers or RF10 and RF10-2F ones at a 300 nM
concentration of each tetramer in individuals in whom 2F virus was detected at the early phase of HIV-1 infection. The percentage of tetramer-positive cells
among CD3+CD8+ 7-AAD T cells was calculated.DISCUSSION
Although it is widely accepted that HIV-1-specific CD8+ T cells
can select virus escape mutations, the relationship between vi-
rus evolution and the adaptation of the T cell response at the clo-
notypic level has remained poorly studied. Previous studies on(B and C) Comparison of TCR repertoire diversity between RF10- and RF10-2F-sp
clonotypes and Simpson’s diversity index for a- (B) and b-chain (C). Statistical a
(D) Longitudinal PBMC samples from three HIV-1 infected HLA-A*24:02+ individua
was sorted for TCR repertoire analysis at the single-cell level. Paired TCR a- and b-B*2705-KK10-specific T cells has shown that two steps are
needed for the virus to escape highly effective WT-specific and
mutant-cross-reactive CTL responses. This process is initiated
by the selection of the L268M mutant virus by WT-specific
CTLs. Nonetheless, the mutant virus can still be controlled by
cross-reactive CTLs with high sensitivity for both WT andmutantecific CTLs. TCR repertoire diversity was assessed by using both the number of
nalysis was conducted by use of the unpaired t test.
ls (KI-092, KI-158, and KI-161) were collected, and each tetramer-positive CTL
chain usages are shown. The heatmap shows the frequency of each clonotype.
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Figure 5. Comparison of Four HLA-A*24:02-
Peptide Structures
(A) Overview of the structures of HLA-A*24:02 in
complex with the four indicated peptides. RF10,
RF10-2F, RW8, and RW8-2F are exhibited in green,
yellow, magenta, and cyan, respectively. Both
RF10 andRF10-2F display featured conformations,
whereas bothRW8andRW8-2F display featureless
ones. The peptides are shown as ribbon models.
(B and C) Structural comparison between two
paired peptides: RF10 and RF10-2F (B); and RW8
and RW8-2F (C). Hydrogen bonds are shown as
black dashes.antigens. In some individuals, these CTLs drive the occurrence
of a secondmutation, R264K in KK10, which abrogates the bind-
ing of the KK10 epitope to the HLA-B*2705 molecule so that no
new CTLs can be induced by this mutant epitope. However, the
additional compensatory mutation S173A in p24 is needed to
rescue virus replicative capacity, which is directly impacted by
the R264K mutation. Our present study using CD8+ T cells spe-
cific for a HLA-A*24:02-restricted Nef epitope has provided new
insights into the HIV-1 escape and T cell clonotype dynamics.
We showed that the virus, through a single step of F mutation
at position 2, could generate a variant with both TCR- and
HLA-binding escape properties, differentially affecting T cells
specific for the superimposed epitopes RF10 and RW8. Our re-
sults indicate that RF10-WT-specific CTLs, together with RW8
cross-reactive CTLs, could drive the selection of the same
escape mutation, 2F. However, after emergence of this muta-
tion, different effects of this variant on the T cell evolution were
observed. The appearance of the RF10-2F epitope was associ-
ated with the de novo induction of mutant-specific CTLs with
entirely different clonotypes. In contrast, the RW8-2F epitope
failed to elicit a new T cell repertoire. In sum, the present work2286 Cell Reports 15, 2279–2291, June 7, 2016describes an original double escape in
TCR recognition and HLA-binding affin-
ity, associated with a single mutation in
the epitope, which had differential im-
pacts on superimposed HIV epitopes.
This highlights the high diversity of sce-
narios related to the molecular arms
race between a virus and the immune
response, and it provides refined mecha-
nistic insights into the evolution of the
virus at the population level.
Molecular and mechanistic support
to explain the differences in TCR reper-
toire was derived from our X-ray crystal-
lographic data. Both mutant peptides
(RF10-2F and RW8-2F) lacked a critical
hydrogen bond interaction between the
primary anchor residue P2 of the peptide
and the H70 residue in HLA-A*24:02. The
weaker binding of the mutant peptides
to HLA-A*24:02 was most likely caused
by changes in the water-molecule-medi-
ated hydrogen bond network, althoughwe cannot formally exclude the possibility that the altered water
network was the result, rather than the cause, of binding and
stability changes. In the absence of enthalpy-entropy compen-
sation data, we interpret the altered TCR recognition as being
similar to the stability-enhancing effect of water-mediated
hydrogen bonding in collagen and collagen-binding adhesin in-
teractions (Vitagliano et al., 2011). The binding stability of RF10-
2F was similar to that of the RW8-WT epitope and greater than
that of RW8-2F, which was unable to induce new T cell re-
sponses. The RF10-2F peptide could still be effectively pre-
sented at the surface of HIV-1-infected cells and recognized
by TCRs. In line with these results, previous studies showed
that the stability of the pMHC is critical in the presentation of
epitopes to T cells, because an unstable pMHC will be present
at lower concentrations or absent on the surface of antigen-
presenting cells (Ahlers and Belyakov, 2010; Busch and Pamer,
1998; Harndahl et al., 2012; Sijts and Pamer, 1997; van der
Burg et al., 1996). Our results support the concept that the sta-
bilization of escape mutant epitopes appears to be the main
driver for the induction of a new T cell repertoire toward escape
epitopes.
Figure 6. Detailed Comparison of Water Molecules in the Four Structures of HLA-A*24:02 Molecules
(A–D) Water-mediated hydrogen bonds between HLA and peptide residues are shown as dotted lines in black. The red spheres represent water molecules.
(A) RW8 (magenta), (B) RW8-2F (cyan), (C) RF10 (green), and (D) RF10-2F (yellow).Given that the side chains of 10-mer peptide residues at P4
and P6 protrude and can be recognized by TCRs, the differences
in the number of water molecules around RF10-WT and RF10-2F
P5 residues would affect the hydrogen bond network around the
TCR recognition site (Shimizu et al., 2013). The RF10-2F peptide
was surrounded by a greater number of watermolecules than the
RF10-WT peptide. A recent crystallographic study suggested
that the differences in the water-mediated hydrogen bond
network between WT and mutant 10-mer peptides may affect
TCR recognition (Shimizu et al., 2013). In addition, we also
observed two additional hydrogen bonds at the P1 residue of
the RF10-2F peptide, suggesting that conformational changes
within RF10-2F may have played a minor role in the escape
from RF10-specific CTLs, although we cannot exclude the pos-
sibility that the changes were simply caused by the flexibility of
the arginine residue (Liu et al., 2011).
Despite the instability of the RW8-2F/HLA-A*24:02 complex,
the RW8-2F peptide could still maintain exogenous binding
to the HLA molecule, as was exemplified by our finding that
RW8-specific CTLs could be cross-reactive and recognize simi-
larly both exogenously presented RW8 and RW8-2F peptides.
The conformational features of the peptides emerge here as
key factors to determine the diversity and cross-reactive nature
of TCRs (Nikolich-Zugich et al., 2004). The featureless con-
formations of the RW8-WT and RW8-2F epitopes within the
HLA-A*24:02 molecule likely allowed RW8-specific TCRs toaccommodate both peptides without difficulty and explain why
RW8-specific CTLs could be cross-reactive, even before the
emergence of the 2F variant. In contrast, like the RF10-WT
epitope, RF10-2F still retained a featured conformation within
the HLA-A*24:02 molecule. This implies the recruitment of a
new clonotypic repertoire specific for the 2F variant, one with
TCR characteristics equivalent to those of the WT-specific
repertoire, as highlighted by the similar TCR diversity between
RF10- and RF10-2F-specific T cells.
Although several epitopes restricted by other HLA alleles have
been identified in this region, only HLA-B*35:01 and HLA-A*02
molecules, found in the Japanese population, may contribute
to the selection of the 2F mutant. HLA-B*35:01-restricted YF9
and HLA-A*02-restricted PL10 epitopes are superimposed in
RF10 (Choppin et al., 2001). Our recent study of HLA-associated
polymorphism (HLA-AP) showed no HLA-AP with HLA-B*35:01
and HLA-A*02 within this epitope, indicating that there is no
accumulation of mutant epitopes selected by other HLA alleles
in this region (Chikata et al., 2014). The F mutation at position
1 might affect YF9-specific CTL recognition although there is
no evidence so far for this possibility.
In the present study, we elucidated the molecular mechanism
of 2F mutant accumulation in the Japanese population and high-
lighted the relationship between clonotypic changes in T cells
and mutant virus evolution. We showed that one mutation within
two superimposed peptides yielded two different types ofCell Reports 15, 2279–2291, June 7, 2016 2287
Figure 7. Effects of the 2F Mutants on Peptide-MHC Binding
Stability and T Cell Recognition
(A) The stability of peptide binding to HLA-A*24:02 molecules was determined
by using RMA-S-A*24:02 cells. The cells were incubated at 26C with a
250-mM concentration of each of the four indicated peptides for 1 hr, and then
the cells were incubated at 37C for 3 hr. After the free, unbound peptide had
been washed out, cells were collected at each indicated time point. The
relative mean fluorescence (MFI) was measured and plotted as percentage of
maximal fluorescence, as described in Experimental Procedures.
(B) Effects of peptide-MHC stability on CTL recognition. C1R-A2402 cells, as
target cells, were pre-pulsed with each of the four indicated peptides at a
concentration of 100 nM for 1 hr and then washed. A portion of the resultant
peptide-loaded cells was taken at each indicated time point and then co-
culturedwith the CTL52 or CTL189 clone at an E:T ratio of 1:1 for the chromium
release assay. Results are given as the mean ± SD of triplicate assays. The
statistics were calculated by performing the unpaired t test.
*p < 0.05; **p < 0.01; ***p < 0.001.outcome, on the one hand inducing a new T cell repertoire and,
on the other, preventing the induction of mutant-specific CD8+
T cells. HLA binding stability and the conformational feature
of the mutant antigens determined this difference. Thus, the
same escape mutations in two different superimposed epitopes
changed the ability of HIV-1 to elicit immune responses in HIV-1-
infected individuals during co-evolution of HIV-1 and CTLs.
Given that recent population-based studies indicate that viral
evolution in response to HLA-mediated immune pressure follows
predictable patterns, the study of immune-driven HIV-1 escape
would help us to develop strategies for an effective vaccine
(Brumme et al., 2009; Chikata et al., 2014; Huang et al., 2011;
Rousseau et al., 2008). Taking into consideration that the evolu-
tion of HIV-1 is central for the design of vaccines in order to be
able to control mutant viruses or their emergence, the design2288 Cell Reports 15, 2279–2291, June 7, 2016of vaccines that include apparently immunogenic escape vari-
ants needs to be carefully considered. The present work illus-
trates this point well. Initial observations may argue in favor of
using 2F as the immunogen. The 2F variant is increasingly prev-
alent in the population, and it appears to be immunological since
2F RF10-specific CD8+ T cells are detected in HIV-1-infected
patients. However, in reality, using such an epitope in an immu-
nogenmay actually be disadvantageous. Due to its reduced HLA
binding stability, the 2F variant is likely to be poor at inducing
CD8+ T cell responses—in particular, those specific to RW8.
Moreover, most effective RF10-2F specific responses will not
be cross-reactive and, therefore, would provide no control of
WT viruses. Overall, the 2F variant is likely to be poorly immuno-
genic, and its use in vaccines would result overall in weak effi-
cacy. This observation might not be an isolated case, as it has
been estimated that approximately 20% of HLA-associated
polymorphisms occur at anchor positions and, moreover, that
the mutations were predicted to confer an average 10-fold
reduction in pMHC binding affinity (Bronke et al., 2013; Carlson
et al., 2015). Therefore, a rational design of effective T cell vac-
cines and immunogens requires a very deep understanding of
the molecular mechanisms underlying the induction of specific
T cell responses against HIV, certainly to levels of depth not
anticipated initially.
EXPERIMENTAL PROCEDURES
Ethics Statement
All 13 HLA-A*24:02+ treatment-naive HIV-1-infected individuals were recruited
from the National Center for Global Health and Medicine (Table S1). The study
was approved by the ethics committees of Kumamoto University and the
National Center for Global Health and Medicine. Informed consent was ob-
tained from all individuals in accordance with the Declaration of Helsinki.
HLA types were determined by standard sequence-based genotyping at the
HLA Laboratory, Kyoto, Japan.
HIV-1-Specific CTL Clones
Antigen-specific CTL cloneswere generated as previously described (Fujiwara
et al., 2008). Briefly, RW8 bulk CTLs were obtained by stimulating PBMCs from
KI-158 with RW8 peptides; then, CTL clones were generated from the cell lines
by the limiting dilution method.
Tetramer Staining
HLA-A*24:02-tetrameric complexes were synthesized as previously described
(Altman et al., 1996). For tetramer staining, CTL clones or individual PBMCs
were stained with WT or 2F tetramers at various concentrations or with a com-
bination of WT and 2F tetramers at 300 nM for RW8 and RF10 CTLs at 37C for
30 min. The cells were subsequently stained with CD3 (fluorescein isothiocy-
anate; FITC), CD8 (Pacific blue), and 7AAD at 4C for 30 min.
Cell Line
C1R-A*2402 andRMA-S-A*2402 cells were generated as previously described
(Ikeda-Moore et al., 1997; Karaki et al., 1993; Sun et al., 2014; Takamiya et al.,
1994).RMA-Scells are aTAP2-deficiencycell linederived fromRMAcells. They
stably express high levels of empty MHC molecules when cultured at 26C
but very low levels at 37C. These cell lines were cultured in R5 medium with
0.2 mg/ml hygromycin B.
51Cr Release Assay
The cytotoxic potential of CTL clones against C1R-A*24:02 prepulsed with
appropriate peptides at various concentrations (0–100 nM) was determined as
previously described (Fujiwara and Takiguchi, 2007). Effector cells were co-
cultured for 4 hr at 37C with target cells at an effector:target (E:T) ratio of 2:1.
Viral Suppression Assay
Two modified HIV-1 virus lab strains, NL-432-10F (WT) and NL-432-2F10F
(2F), were used in these assays (Fujiwara et al., 2008). The ability of HIV-1-spe-
cific CTLs to suppress HIV-1 replication was examined as previously
described (Fujiwara et al., 2008). Briefly, activated primary CD4+ T cells were
infected with WT or 2F virus for 6 hr before being washed with R10 medium.
The cells were then co-cultured with HIV-1-specific CTL clones at various
E:T ratios. We collected 10 ml of culture supernatant at day 6, and then the
p24 level in it was determined by ELISA.
Replication Kinetics Assay
The replication kinetics of the WT and 2F viruses were examined as previously
described (Akahoshi et al., 2012). In brief, CD4+ T cells (23 106) were infected
with the 500 blue-cell-forming units (BFU) of eitherWT virus or 2F virus; the cul-
ture supernatant was then collected from day 2 to day 10 post-infection. The
concentration of supernatant p24 antigen was measured by using ELISA.
In Vitro Competitive Viral Suppression Assay
Primary CD4 T cells fromHLA-A*24:02+ HIV-1-negative individuals were co-in-
fected with WT and 2F mutant viruses at a ratio of 9:1. The infected cells were
incubated with or without CTL52 or CTL170 at an E:T ratio of 1:1. The culture
supernatants were collected from day 3 to day 7, after which the p24 concen-
tration was measured by ELISA (Kawashima et al., 2010). Two microliters of
supernatant was directly used as the template for PCR amplification with a Su-
perscript III One-Step RT-PCR kit (Invitrogen), and the same primer sets as
described earlier were used (Fujiwara et al., 2008). The ratio of WT and 2F vi-
ruses in the supernatant was determined by the relative peak height on the
sequencing electrogram obtained with sequence scanner v1.0.
Ex Vivo Single-Cell TCR Repertoire Analysis and Assessment of TCR
Diversity
RW8 cross-reactive and RF10-2F tetramer+CD3+CD8+7-AAD cells from cry-
opreserved PBMC samples were sorted into a 96-well plate by using a BD
FACS Aria I. The PCR and sequencing were performed as previously
described (Sun et al., 2012, 2014). The diversity of TCR clonotypes was calcu-
lated by using both the number of different clonotypes and Simpson’s diversity
index for both a- and b chains (Venturi et al., 2007).
Peptide-MHC Dissociation Assay
The binding stability of four peptides to HLA-A*24:02 molecules was deter-
mined by using RMA-S-A*24:02 cells. The cells were cultured at 26C for
14–18 hr and then continued to be incubated at 26C for 1 hr in the presence
of 250 mM synthetic RW8, RW8-2F, RF10, or RF10-2F and medium only as a
negative control. Then they were incubated at 37C for 3 hr, subsequently
washed three times with cold culture medium, and thereafter suspended in
culture medium. After 0, 1, 2, 4, or 6 hr, samples were taken, washed twice,
and immediately stained with monoclonal antibody (mAb) A11.1 for 30 min,
washed, and stained with FITC-conjugated sheep anti-mouse immunoglob-
ulin G (IgG) as the secondary antibody (Ab). Expression of HLA-A*24:02 was
determined by flow cytometry. The decay of A*24:02-peptide complexes
was determined as the percent median fluorescence intensity (MFI) remaining:
(MFIt(+pep)MFIt(pep))/(MFIt = 0(+pep)MFIt = 0(pep)) (Brooks et al., 1998), and
the peptide binding stability was presented as the time required for 50%decay
of the HLA molecules (DT50), as calculated by linear regression analysis (Dong
et al., 2004). The 51Cr release assay was conducted as described earlier;
briefly, after 0, 1, 2, 4, or 6 hr, labeled cells were harvested and washed and
then used as target cells in killing assays, with an E:T ratio of 1:1. The specific
lysis activity was calculated as described earlier (Fujiwara and Takiguchi,
2007).
Crystallization, Data Collection, and Processing
Soluble peptide-HLA-A*24:02 complexes were prepared as previously
described (Shi et al., 2011; Sun et al., 2014). The individual proteins were
then purified by SuperdexTM 200 10/300 GL gel-filtration chromatography
(GE Healthcare). All crystallization attempts were performed by the hanging
drop vapor diffusion method at 18C with a protein/reservoir drop ratio
of 1:1. Diffraction data were collected by using beamline NE3A in the KEKsynchrotron facility (Tsukuba, Japan) and an ADSCQ270 imaging-plate detec-
tor at awavelength of 1.0 A˚. Datawere indexed, integrated, and scaled by using
HKL2000 (Minor, 1997). Data were analyzed by molecular replacement using
MolRep in CCP4 (Collaborative Computational Project, Number 4, 1994). We
used the A24VYG molecule (PDB: 2BCK) as the search model. All of the struc-
tures were further refined by several rounds of refinement using the PHENIX
program (Adams et al., 2002). The data collection and refinement statistics
are given in Table S2. The detailed interactions betweenHLA-A*24:02 and pep-
tide were analyzed by using Contact in the CCP4 package (Collaborative
Computational Project, Number 4, 1994). The PyMOLMolecular Graphics Sys-
tem (Schro¨dinger; http://www.pymol.org) was used to prepare figures.
Statistical Analyses
We calculated the significance of differences for data given in Figures 1B, 3B,
3C, and 7 by using the unpaired t test; and p values of <0.05 were considered
to be significant. Results were reported as the mean ± SD.
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The accession numbers for the structures of pMHCs of HLA-A*24:02-RF10,
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reported in this paper are PDB: 5HGH, 5HGD, 5HGB, and 5HGA, respectively.
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